Use of CSF biomarkers in Alzheimer’s disease clinical trials

被引:0
作者
K. Blennow
H. Zetterberg
机构
[1] the Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Laboratory
[2] The Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Lab
[3] Sahlgrenska University Hospital,undefined
来源
JNHA - The Journal of Nutrition, Health and Aging | 2009年 / 13卷
关键词
Mild Cognitive Impairment; Lewy Body Dementia; BACE1 Inhibitor; Secretase Inhibitor; Mild Cognitive Impairment Case;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 198 条
[1]  
Blennow K.(2006)Alzheimer’s disease Lancet 368 387-403
[2]  
de Leon M.J.(1993)Low frequency of post-lumbar puncture headache in demented patients Acta Neurol Scand 1 88 221-223
[3]  
Zetterberg H.(2005)Safety and acceptability of the research lumbar puncture Alzheimer Dis Assoc Disord 19 220-225
[4]  
Blennow K.(2001)Evaluation of CSF-tau and CSF-A 42 as diagnostic markers for Alzheimer’s disease in clinical practice Arch Neurol 58 373-379
[5]  
Wallin A.(2003)Cerebrospinal fluid markers for incipient Alzheimer’s disease Lancet Neurology 2 605-613
[6]  
Häger O.(2005)CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment Expert Rev Mol Diagn 5 661-672
[7]  
Peskind E.R.(2002)Differential diagnsis of Alzheimer’s disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 Arch Neurol 59 1267-1272
[8]  
Riekse R.(2004)Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease: A Comparative Cerebrospinal Fluid Study Arch Gen Psychiatry 61 95-102
[9]  
Quinn J.F.(2006)Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 228-234
[10]  
Kaye J.(2003)Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds Dem Geriatr Cogn Disord 15 169-176